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ABSTRACT
Emerging evidence suggests that host dendritic cells (DC) initiate and regulate graft-versus-host and graft-
versus-tumor reactions after allogeneic hematopoietic cell transplantation (HCT). Even though decades of
experimentation in the preclinical canine HCT model have substantially improved our understanding of the
biology and safety of HCT in human patients, the in vivo phenotype of potent antigen-presenting cells in dogs
is poorly defined. Therefore, peripheral blood leukocytes were obtained from dogs treated with recombinant
human Flt3-ligand and phenotypically distinct cell populations, including putative DC, were purified by 4-color
flow-cytometry and tested for their stimulatory potential in allogeneic mixed lymphocyte cultures (MLC).
Cells characterized by surface expression of CD11c and HLA-DR, and absence of expression of CD14 and
DM5, a marker of mature granulocytes, were found to be highly potent stimulators in allogeneic MLC. In
contrast, all other immunophenotypically different cell populations tested had either weak or absent allostimu-
latory potential. Transmission electron microscopy of CD11c/HLA-DR/CD14/DM5 cells revealed the
morphology similar to that described for DC in humans and ex vivo-generated canine DC, including long
cytoplasmic extensions, discrete lysosomes, and an abundant Golgi apparatus and endoplasmatic reticulum. In
summary, CD11c/HLA-DR/CD14/DM5 cells obtained from canine peripheral blood have functional and
morphologic characteristics similar to those of human myeloid DC.
© 2007 American Society for Blood and Marrow Transplantation
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Dendritic cells (DC) comprise a specialized system
or presenting antigen to naïve or quiescent T cells,
nd consequently play a central role in the induction
f T cell and B cell immunity in vivo [1]. Immature
C capture microbial or viral antigens in peripheral
issues and migrate to lymphoid organs where, after
aturation, they display antigen-derived peptides in
he context of MHC molecules. Antigen-speciﬁc T
ells are activated through recognition of (1) an anti-
en-speciﬁc signal (antigen-major histocompatibility
omplex complex; “signal 1”) and (2) a “nonspeciﬁc”
ostimulatory signal (“signal 2”) displayed on the DC
urface. Given that DC change in phenotype during
heir lifespan and cell surface markers otherwise char-
cteristic for distinct hematopoietic cell lineages are i
286ot speciﬁc for identifying DC, it is difﬁcult to use
hese markers for ontogenic deductions. Thus, the
uestion whether DC originate from a separate lin-
age or belong to the monocyte/macrophage family is
till unresolved.
More recently, host DC have been identiﬁed as
he key initiators and regulators of graft-versus-host
GVH) and graft-versus-tumor (GVT) effects after
llogeneic hematopoietic cell transplantation (HCT)
2-4]. After allogeneic HCT, host DC may be re-
laced by donor cells at a rate depending upon the (1)
ntensity of the preparative regimen, (2) the capacity
f self-renewal of host DC, and (3) the recruitment of
ew donor-derived DC precursors. Hence, the re-
lacement kinetics of host DC by donor DC might
nﬂuence transplantation outcomes including graft-
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Canine Dendritic Cells Generated In Vivo 1287ersus-host disease (GVHD), host-versus-graft reac-
ions that may lead to graft rejection, and GVT effects
hat maintain remission of the underlying malignancy.
Despite the emerging role of host DC in initiating
VHD and GVT responses after allogeneic HCT, po-
ent antigen-presenting cells analogous to those occur-
ing in humans in vivo have not been deﬁned for the
anine model. This is of interest because the random-
red dog model has been extremely useful for improving
he safety and our understanding of the biology of hu-
an HCT. For example, most of the GVHD prophy-
actic regimens, such as methotrexate (MTX)/cyclospor-
ne (CSP) [5] and mycophenolate mofetil (MMF)/CSP
6], have been developed in dogs. More recently, the
og model has helped pioneer nonmyeloablative
CT regimens for human transplantation [7].
In the current study we used a panel of canine-
peciﬁc and crossreacting antihuman monoclonal an-
ibodies (mAbs) to identify DC in peripheral blood of
ogs. We identiﬁed a CD11c/HLA-DR/CD14/
M5 cell population with functional and morpho-
ogic characteristics similar to those described for hu-
an myeloid DC.
ATERIALS AND METHODS
The Institutional Animal Care and Use Com-
ittee of the Fred Hutchinson Cancer Research
enter (FHCRC) approved this study. Standard
are was provided as described previously [8,9].
eagles or miniature mongrel-beagle crossbreeds
n  10) were given daily subcutaneous injection of
00 g/kg recombinant human Flt3-ligand (FL;
mgen, Seattle, WA). Peripheral blood leukocytes
PBL) were obtained from whole blood before and
fter 10 days of FL treatment, hemolyzed, and cryo-
reserved for future testing. The following mono-
lonal antibodies (mAbs) were used for ﬂow cyto-
etric analyses and cell sorting of putative DC:
rimary murine mAbs used in the study were: anti-
uman HLA-DR-APC (G46-6), antihuman CD14-
erCP-Cy5.5 (M5E2) (BD Biosciences, San Jose,
A); anticanine DM5-FITC [10], anticanine CD3-
able 1. Absolute and Relative Changes in Cell Numbers in the Periph
Pre-FL
Cell Type Median Range
hite blood cells (103/L) 11.5 10.2-16.9
ranulocytes (103/L) 7.8 5.4-10.8
ymphocytes (103/L) 3.4 2.3-5.3
onocytes (103/L) 0.6 0.1-2.2
latelets (103/L) 383 267-518
ematocrit (%) 47.8 40.2-50.7
omplete blood counts were obtained prior to (pre-FL) and at the
are absolute cell numbers, and relative changes of morphologicP-values were derived from paired t-tests.ITC (17.6F9) [11], anticanine CD34-FITC (1H6)
12], anticanine CD21-PE (CA2.1D6), anticanine
D4-biotin (1E4) [13], and anticanine CD11c-biotin
CA11.6A1) [14]. Unidirectional mixed lymphocyte
ultures (MLC) using peripheral blood mononuclear
ells (PBMC) isolated by density-gradient centrifuga-
ion were conducted according to established methods
15]. Transmission electron microscopy of sorted
D11c/HLA-DR/CD14/DM5 cells was per-
ormed using a JEM-1010 electron microscope (JEOL
nc., Peabody, MA).
ESULTS
L Treatment Increases Peripheral Blood
onocyte Numbers and the Allostimulatory
otential of Unfractionated Peripheral Blood
eukocytes
To determine whether FL treatment changed the
omposition and thereby increased the allostimulatory
otential of PBL, 10 dogs were given daily subcuta-
eous injections of FL (100 g/kg/day). After 10 days
f FL treatment, we observed a median 1.85-fold
ncrease in PBL (P  .003), which was largely attrib-
table to mobilization of monocytes (median increase,
.1-fold; P .001) and granulocytes (median increase,
.63-fold; P  .03) (Table 1). Additional immunophe-
otypical analyses of cell populations in peripheral
lood of 2 dogs before and after FL treatment showed
hat the number of CD34 hematopoietic progenitor
ells and CD14/DM5 monocytes increased 10.2-
old and 10.6-fold, respectively. There was no signif-
cant change in lymphocyte and platelet counts, and
ematocrit. Compared to untreated control dogs, FL
reatment increased the allostimulatory potential of
BL in MLC by a median of 150% (range: 36%-
00%; P  .002; n  5) (Figure 1).
urification of Putative Dendritic Cells from
hole Blood
To identify the cell population accounting for the
ncreased allostimulatory potential of unfractionated
od of 10 Dogs Treated with Flt3-Ligand
Post-FL
Fold Increase P*Median Range
21.3 13.4-35.3 1.85 .003
12.7 5.8-25.7 1.63 .03
4.4 3.1-6.8 1.28 .26
4.8 2.4-6.7 8.10 <.001
302 262-440 0.79 .08
48.1 40.6-52.6 1.01 .63
tion of FL treatment (post-FL) (100 g/kg/day  10 days). Shown
racterized cell populations pre- and post-FL treatment.eral Blo
comple
ally cha
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M. Mielcarek et al.1288BL after FL treatment, phenotypically different cell
opulations were sorted from post-FL blood and used
s stimulator cells in allogeneic MLC. Purity of sorted
ell populations was 97%. Figure 2A and B shows
he change in forward-scatter/side-scatter (FSC/SSC)
istribution of PBL after 10 days of FL treatment.
he increased white blood cell count after FL treat-
ent was largely attributable to the 10-fold increase in
ells with intermediate FSC/SSC characteristics,
hich were CD14 monocytes. Putative canine DC
ere sorted from post-FL blood using a 3-step ap-
roach. First, cell debris was excluded by establishing
gate according to FSC/SSC characteristics (Gate 1,
igure 3A). Second, a gate was established (Gate 2) to
nclude cells that were CD14 and DM5, thereby
xcluding monocytes and granulocytes (Figure 3B).
inally, HLA-DR/CD11c cells were collected (R5,
igure 3C). Although the CD11c/HLA-DR/
D14/DM5 cell population comprised 0.1% of
re-FL PBL, the median percentage of these cells
mong post-FL PBL was 0.66% (range: 0.16%-
.90%; P  .026; n  7).
D11c/HLA-DR/CD14/DM5 Cells are
otent Stimulators in Allogeneic Mixed
ymphocyte Culture
Sorted CD11c/HLA-DR/CD14/DM5 pu-
ative DC were subsequently tested for their ability to
timulate third-party responders in allogeneic MLC in
omparison to sorted monocytes, granulocytes, and B
ymphocytes (Figure 4). All stimulator populations
ere irradiated (22 Gy) prior to initiation of MLC.
igure 1. Allostimulatory potential of unsorted peripheral blood
eukocytes obtained from dogs before (pre-FL) and after (post-FL)
ompletion of 10 days of Flt3-ligand (FL) treatment. Different
umbers of stimulators cells (5-20  104) obtained from dogs
re-FL and post-FL (100 g/kg/day given subcutaneously for 10
ays) were incubated with constant numbers (1 105) of allogeneic,
hird-party responder cells as described in Materials and Methods.
hown is one representative experiment of 5 experiments. Com-
ared to untreated control dogs, FL treatment increased the MLC
llostimulatory potential of unsorted peripheral blood leukocytes by
median of 150% (range: 36%-900%).ven at low stimulator cell numbers of 5  103/well, tutative DC had strong allostimulatory potential,
hich increased with increasing numbers of stimula-
or cells (Figure 4). Although sorted B lymphocytes
CD21/HLA-DR) had weak allostimulatory poten-
ial, monocytes (CD14/DM5) and granulocytes
DM5/CD14) did not appreciably stimulate re-
ponder cell proliferation.
orphology of CD11c/HLA-DR/CD14/DM5
ells by Transmission Electron Microscopy
Sorted putative DC (CD11c/HLA-DR/CD14/
M5) were characterized by long cytoplasmic pro-
esses by transmission electron microscopy (Figure 5).
hey displayed irregularly shaped nuclei and multive-
icular bodies. In contrast to macrophages and mono-
ytes, which frequently displayed large and dark phago-
ytic vacuoles, putative DC had only small, if any,
ysosomal organelles. Putative DC were further charac-
erized by their abundant Golgi apparatus and endoplas-
ic reticulum.
ISCUSSION
Although the mouse has provided important in-
ights into issues of hematopoiesis and HCT, there
re serious limitations when extrapolating transplan-
ation studies from mice to humans. In mice, for
xample, it is relatively easy to cross histocompatibility
arriers, even including H2, without consistently en-
ountering donor-graft rejection or fatal GVHD, and
urine T cell-depleted (TCD) grafts are much easier
o accomplish than those in dogs or humans [16-18].
n contrast, the random-bred dog model has been
xtremely useful for improving safety and our under-
tanding of the biology of human HCT, because out-
omes in this large animal model closely predict those
n human transplant recipients.
More recent studies in mice suggest that DC initiate
nd regulate GVH and GVT reactions after allogeneic
CT [2-4]. It has been shown, for example, that (1) host
nd not donor antigen-presenting cells are required for
he induction of GVHD in a model in which CD8 T
ells interact with minor MHC molecules presented in
he context of class I, and (2) that donor lymphocyte
nfusions mediate superior GVT effects in mixed com-
ared to full donor chimeras. Both observations support
he critical role of host antigen-presenting cells in initi-
ting and regulating GVH responses after allogeneic
CT. Canine DC, however, are poorly characterized,
nd most of the published literature on canine DC is
ased on cells generated by ex vivo culture using com-
inations of hematopoietic growth factors including
ranulocyte-monocyte colony-stimulating factor (GM-
SF), tumor-necrosis-factor- (TNF-), FL, and inter-
eukin (IL)-4 [19-21]. In this study, we therefore sought
o identify and characterize potent antigen-presenting
Figure 2. Fluorescence activated cell sorting of phenotypically distinct cell populations from peripheral blood of FL-treated dogs. FSC/SSC characteristics of peripheral blood leukocytes before (A) and
after (B) 10 days of FL treatment (100 g/kg/day). Phenotypically distinct cell populations were sorted from post-FL peripheral blood as described in Materials and Methods. The following gates were
combined with Gate 1, which was established according to FSC/SSC characteristics: Gate 2 for B lymphocytes (C); Gates 3 and 4 for monocytes and granulocytes, respectively (D); and Gates 5 and
6 for CD4 and CD8 T cells, respectively (E). Purity of sorted cell populations was 97%. CD34 progenitor cells were not used as stimulator cells in MLC (F).
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M. Mielcarek et al.1290ells that occur in dogs in vivo to apply this knowledge to
uture studies in the canine HCT model.
In humans, DC comprise 1% of PBMCs, mak-
ng the study of these cells difﬁcult. Two phenotyp-
cally distinct DC subtypes have been described.
yeloid DC (or DC1) express HLA-DR, suppos-
dly originate from myeloid marrow precursors
nd, therefore, express myeloid antigens including
D11c, and require the presence of GM-CSF for
heir survival [22-24]. Myeloid DC produce high
evels of IL-12 when stimulated with TNF- or
D40L, and drive T cell differentiation into Th1
22]. Lymphoid DC (or DC2) have been described
n human peripheral blood and lymphoid tissues as
D11c/HLA-DR/CD4/IL-3R plasmacytoid
ells. DC2 cells depend on IL-3 and not on GM-
SF for their survival and differentiation [24,25].
hey have been designated DC2 because, after ap-
ropriate activation, they can induce T cell differ-
ntiation into Th2 cells [22].
igure 3. Phenotypic characterization of putative dendritic cells (D
pproach. First, cell debris was excluded by establishing a gate accor
o exclude all cells that were CD14 (monocytes) and DM5 (gra
hus, putative DC were deﬁned as live gated cells that were HLA
igure 4. Functional characterization of sorted cell populations in
orted from FL-treated dogs as described in Materials and Methods
nto mixed lymphocyte cultures using constant numbers (1  105)
xperiments.Applying the panel of canine-speciﬁc or crossre-
cting mAbs available to us, we found that cells with
n immunophenotype similar to that of myeloid DC
n humans (CD11c/HLA-DR/CD14) were, un-
er steady-state conditions, also extremely rare in the
eripheral blood of dogs. To facilitate the isolation of
hese rare cells in numbers sufﬁcient for further func-
ional and morphologic characterization, dogs were
reated with recombinant human FL, a hematopoietic
rowth factor known to crossreact with canine cells
21,26]. FL has been shown to expand both the num-
er of myeloid and lymphoid DC subsets in mice and
umans [27-29]. Ten days of FL treatment resulted in
doubling of the total white blood cell (WBC) count,
hich was largely attributable to an approximately
0-fold increase in the number of CD14 monocytes.
oreover, FL treatment led to the emergence of a
istinct CD11c/HLA-DR/CD14 cell population,
surface marker proﬁle consistent with that of my-
loid DC in humans. These putative DC were further
tative canine DC were sorted from post-FL blood using a 3-step
FSC/SSC characteristics (Gate 1) (A). Second, Gate 2 was chosen
es) (B). Third, HLA-DR/CD11c cells (R5) were collected (C).
CD11c/DM5/CD14.
ymphocyte cultures. Phenotypically distinct cells populations were
ng numbers (5-20  103) of irradiated stimulator cells were placed
geneic, third-party responder cells. Shown is 1 of 6 representativeC). Pu
ding to
nulocytmixed l
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Canine Dendritic Cells Generated In Vivo 1291eﬁned by the absence of DM5 expression, a marker
ighly expressed on mature granulocytes of dogs.
As few as 5  103 irradiated CD11c/HLA-DR/
D14/DM5 cells elicited strong proliferative T cell
esponses in unidirectional, allogeneic MLC. At re-
ponder-stimulator ratios of 20:1, CD21/HLA-DR
cells and CD14/DM5 monocytes were at least
0-fold less effective than putative DC in stimulating
llogeneic T cells. CD11cdim/HLA-DR/CD14/
M5 were also strong stimulators in MLC (not
hown), but further characterization of these cells as
he possible equivalent of plasmacytoid DC in humans
as limited by the lack of canine-speciﬁc reagents (ie,
nti-IL-3R). Transmission electron microscopy of
D11c/HLA-DR/CD14/DM5 cells revealed
morphology similar to that described for myeloid
C in humans and for ex vivo-generated canine
C, including long cytoplasmic extensions, discrete
ysosomes, and an abundant Golgi apparatus and
ndoplasmatic reticulum [20,21,30,31].
Whether phenotype and function described for
anine DC generated in vivo after FL treatment can be
xtrapolated to DC present under steady-state condi-
ions remains unknown. The majority of FL-mobilized
igure 5. Transmission electron microscopy of sorted putative de
xamined by transmission electron microscopy as described in M
ontrast to macrophages, which frequently displayed large and dark p
y long cytoplasmic processes (B,C), only small, if any, lysosom
eticulum (D). Multivesicular bodies (A and C; open arrowheads).C1 and DC2 in healthy human volunteers and can- Wer patients have been shown to be phenotypically
nd functionally more immature than their steady-
tate counterparts, which was evidenced by de-
reased IL-12 production and allostimulatory po-
ential [32-34]. Their overall immunophenotype
CD11c/HLA-DR/CD14), however, was not
ifferent. If FL treatment also resulted in expansion of
elatively immature DC in dogs, the allostimulatory po-
ential of their steady-state counterparts would be ex-
ected to be even greater. Thus, the use of FL-generated
D11c/HLA-DR/CD14/DM5 cells in our study
ight have resulted in an underestimation of the allo-
timulatory potential of steady-state DC in dogs.
In conclusion, the identiﬁcation of highly potent
ntigen-presenting cells in the peripheral blood of
ogs, which may represent the equivalent of myeloid
C in humans, will enable us to apply this knowledge
o the design and interpretation of future studies in
he canine HCT model.
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